What We're Reading: Page 106
Industry reads hand-picked by our editors
Nov 08, 2022
-
STAT
J&J’s Mammen out of the running for Biogen CEO post
-
Reuters
U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead
-
FierceBiotech
ADC therapy sidelined after FDA nixes accelerated review chance
-
The Wall Street Journal
Political Gridlock Would Bring Big Pharma a Sigh of Relief
Nov 07, 2022
Nov 04, 2022
-
The Wall Street Journal
Teva Pharmaceutical to Replace CEO Kare Schultz
-
Stat News
FDA approval decision on Apellis Pharma eye disease drug delayed
-
Bloomberg
Sanofi, Astra Drug That Protects Infants from RSV Approved in Europe
-
Evaluate Vantage
If at first... pharma’s most drawn-out development timelines revealed
Nov 03, 2022
Nov 02, 2022
-
The Wall Street Journal
JPMorgan Launches Life-Sciences Venture Group
-
Evaluate Vantage
GSK struggles to shake Zantac and pipeline concerns
-
PR Week
FDA Commissioner Robert Califf plans to keep tweeting amid Elon Musk upheaval
Nov 01, 2022
-
Bloomberg
The Quest for a Nonaddictive Painkiller
-
The Atlantic
The End of Evusheld
-
Politico
FDA says providers offering medication abortion before pregnancy have gone rogue
-
LifeSciVC
Playing Small Ball
Oct 31, 2022
-
The Wall Street Journal
Pfizer Squares Off With Merck, Other Drugmakers Over Lucrative Pneumonia Vaccines
-
Bloomberg
Hong Kong Has a Biotech Talent Problem
-
Reuters
China bars GSK’s prostate drug from national drug bulk-buy programme
-
FierceBiotech
Y-mAbs’ rare disease drug roundly rejected by FDA adcomm over weakness of single-arm trial
Previous
